These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

788 related items for PubMed ID: 15978265

  • 21. [Significance of serum PTH (7-84) as a reliable nutritional marker in hemodialysis patients].
    Shidara K, Inaba M, Kumeda Y, Imanishi Y, Tahara H, Ishimura E, Nishizawa Y, Yamakawa T, Okuno S.
    Clin Calcium; 2005 Sep; 15 Suppl 1():102-4; discussion 104-5. PubMed ID: 16279018
    [Abstract] [Full Text] [Related]

  • 22. [Biochemical markers of bone formation in hemodialysis and after allotransplantation of cadaveric kidney].
    Ermakova IP, Pronchenko IA, Buzulina VP, Nikonova TIu, Borisova AV.
    Ter Arkh; 2006 Sep; 78(10):73-6. PubMed ID: 17180944
    [Abstract] [Full Text] [Related]

  • 23. Effects of vitamin K2 in hemodialysis patients with low serum parathyroid hormone levels.
    Nakashima A, Yorioka N, Doi S, Masaki T, Ito T, Harada S.
    Bone; 2004 Mar; 34(3):579-83. PubMed ID: 15003806
    [Abstract] [Full Text] [Related]

  • 24. Significance of serum CrossLaps as a predictor of changes in bone mineral density during estrogen replacement therapy; comparison with serum carboxyterminal telopeptide of type I collagen and urinary deoxypyridinoline.
    Okabe R, Inaba M, Nakatsuka K, Miki T, Naka H, Moriguchi A, Nishizawa Y.
    J Bone Miner Metab; 2004 Mar; 22(2):127-31. PubMed ID: 14999523
    [Abstract] [Full Text] [Related]

  • 25. Gender variation in PTH sensitivity and rhythmicity following growth hormone replacement in adult growth hormone-deficient patients.
    White HD, Ahmad AM, Syed AA, Clewes A, Peter R, Vora JP, Fraser WD.
    Clin Endocrinol (Oxf); 2004 Apr; 60(4):516-26. PubMed ID: 15049968
    [Abstract] [Full Text] [Related]

  • 26. Effect of parathyroidectomy on bone mineral density in hemodialysis patients with secondary hyperparathyroidism: possible usefulness of preoperative determination of parathyroid hormone level for prediction of bone regain.
    Yano S, Sugimoto T, Tsukamoto T, Yamaguchi T, Hattori T, Sekita KI, Kaji H, Hattori S, Kobayashi A, Chihara K.
    Horm Metab Res; 2003 Apr; 35(4):259-64. PubMed ID: 12778370
    [Abstract] [Full Text] [Related]

  • 27. Bone mineral density in patients with growth hormone deficiency: does a gender difference exist?
    Hitz MF, Jensen JE, Eskildsen PC.
    Clin Endocrinol (Oxf); 2006 Dec; 65(6):783-91. PubMed ID: 17121531
    [Abstract] [Full Text] [Related]

  • 28. Change in serum undercarboxylated osteocalcin concentration in bilaterally oophorectomized women.
    Yasui T, Uemura H, Tomita J, Miyatani Y, Yamada M, Kuwahara A, Matsuzaki T, Maegawa M, Miura M, Irahara M.
    Maturitas; 2007 Mar 20; 56(3):288-96. PubMed ID: 17030103
    [Abstract] [Full Text] [Related]

  • 29. Serum concentrations of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis.
    Al-Awadhi A, Olusi S, Al-Zaid N, Prabha K.
    J Rheumatol; 1999 Jun 20; 26(6):1250-6. PubMed ID: 10381038
    [Abstract] [Full Text] [Related]

  • 30. Rapid bone loss is associated with increased levels of biochemical markers.
    Ross PD, Knowlton W.
    J Bone Miner Res; 1998 Feb 20; 13(2):297-302. PubMed ID: 9495524
    [Abstract] [Full Text] [Related]

  • 31. [Clinical significance of PTH (1-84) and PTH (7-84) in patients with predialysis chronic renal failure in relation to bone metabolism markers].
    Tsuchida T, Ishimura E, Hirowatari K, Matsumoto N, Jono S, Miki T, Inaba M, Nishizawa Y.
    Clin Calcium; 2005 Sep 20; 15 Suppl 1():156-60; discussion 160. PubMed ID: 16272650
    [Abstract] [Full Text] [Related]

  • 32. [Evaluation of cancer-induced bone diseases by bone metabolic marker].
    Takahashi S.
    Clin Calcium; 2006 Apr 20; 16(4):581- 90. PubMed ID: 16582508
    [Abstract] [Full Text] [Related]

  • 33. Elevation of intact parathyroid hormone level is a risk factor for low bone mineral density in pretransplant patients with liver diseases.
    Bai XL, Liang TB, Wu LH, Li DL, Geng L, Wang WL, Shen Y, Zhang M, Zheng SS.
    Transplant Proc; 2007 Dec 20; 39(10):3182-5. PubMed ID: 18089348
    [Abstract] [Full Text] [Related]

  • 34. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients.
    Couttenye MM, D'Haese PC, Van Hoof VO, Lemoniatou E, Goodman W, Verpooten GA, De Broe ME.
    Nephrol Dial Transplant; 1996 Jun 20; 11(6):1065-72. PubMed ID: 8671970
    [Abstract] [Full Text] [Related]

  • 35. [Hemodialysis with 2.5 mEq/L of calcium in relative hypoparathyroidism: long-term effects on bone mass].
    Sánchez Perales MC, García Cortés MJ, Borrego FJ, Fernández Martínez S, Borrego J, Pérez del Barrio P, Liébana A, Pérez Bañasco V.
    Nefrologia; 2000 Jun 20; 20(3):254-61. PubMed ID: 10917002
    [Abstract] [Full Text] [Related]

  • 36. The usefulness of bone metabolic indices for the prediction of changes in bone mineral density after parathyroidectomy in patients with primary hyperparathyroidism.
    Kaji H, Nomura R, Yamauchi M, Chihara K, Sugimoto T.
    Horm Metab Res; 2006 Jun 20; 38(6):411-6. PubMed ID: 16823724
    [Abstract] [Full Text] [Related]

  • 37. Effects of 12 months of recombinant growth hormone therapy on parameters of bone metabolism and bone mineral density in patients on chronic hemodialysis.
    Kotzmann H, Riedl M, Pietschmann P, Schmidt A, Schuster E, Kreuzer S, Kainberger F, Frisch H, Geyer G, Hörl WH, Mayer G, Luger A.
    J Nephrol; 2004 Jun 20; 17(1):87-94. PubMed ID: 15151263
    [Abstract] [Full Text] [Related]

  • 38. [Bone biomarkers in haemodialysis patients: bone alkaline phosphatase or ß-Crosslaps?].
    Jean G, Souberbielle JC, Granjon S, Lorriaux C, Hurot JM, Mayor B, Deleaval P, Chazot C.
    Nephrol Ther; 2013 Jun 20; 9(3):154-9. PubMed ID: 23545236
    [Abstract] [Full Text] [Related]

  • 39. Mineral bone disorder and osteoporosis in hemodialysis patients.
    Slouma M, Sahli H, Bahlous A, Laadhar L, Smaoui W, Rekik S, Gharsallah I, Sallami M, Moussa FB, Elleuch M, Cheour E.
    Adv Rheumatol; 2020 Feb 26; 60(1):15. PubMed ID: 32102689
    [Abstract] [Full Text] [Related]

  • 40. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD, Licata AA, Reginster JY, Crans GG, Chen P, Misurski DA, Wagman RB, Mitlak BH.
    Bone; 2006 Aug 26; 39(2):237-43. PubMed ID: 16563890
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 40.